midazolam + sufentanil + cisatracurium + etomidate

This combination regimen is used for the induction of general anesthesia, specifically as described in clinical research conducted by the Second Affiliated Hospital of Xi'an Jiaotong University. It comprises four distinct pharmacological agents: midazolam (a benzodiazepine for sedation and anxiolysis), sufentanil (a potent opioid analgesic), cisatracurium (a non-depolarizing neuromuscular blocking agent), and etomidate (a short-acting intravenous hypnotic). The combination is designed to provide a rapid and stable transition to an unconscious state while ensuring analgesia and muscle relaxation for surgical procedures. In the referenced Phase 4 trial, this induction protocol was used to study the perioperative effects of dexmedetomidine on glucose and insulin levels in elderly diabetic patients.

Other names

general anesthesia induction